Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is FAST-Forward/ultra-hypofractionation suitable for an early-stage breast patient after a lumpectomy with oncoplastic reduction?
Answer from: Radiation Oncologist at Community Practice
Yes, FAST-Forward is fine after oncoplastic reduction as long as dose homogeneity criteria can be met (V105 < 5%).
Comments
Radiation Oncologist at Indiana University Health
@Sushil Beriwal, is there any thought that if a pa...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
As long as dosimetric and clinical criteria are me...
15540
15544
Sign In
or
Register
to read more
26566
Related Questions
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
When using hypofractionated whole breast radiotherapy with a simultaneous integrated boost to the lumpectomy cavity, what IGRT strategy do you use?
Would you consider whole breast re-irradiation in a patient with a second/recurrent breast cancer and prior history of breast radiation therapy many years ago, if the tumor characteristics are not amenable to partial breast re-irradiation?
What is an acceptable upper limit for ipsilateral lung V8 Gy when using the Fast Forward regimen with high tangents to cover limited axillary disease?
How would you approach a patient with a 12 mm recurrence of the left implant-based breast reconstruction 17 years after her initial diagnosis?
When do you start adjuvant radiation with areas of delayed wound healing after reduction mammoplasty?
For a patient who previously underwent PBI and then developed a second ipsilateral primary, would you offer repeat PBI?
How do you approach breast hypofractionation RNI with the results of the Skagen Trial 1?
What is your preferred comprehensive nodal irradiation approach in non-metastatic breast cancer patients with underlying respiratory diseases or poor baseline respiratory function in light of the findings from the RadComp Trial?
How does a pathological CR to neoadjuvant chemotherapy influence your practice for the use of bolus with adjuvant PMRT patients without inflammatory breast cancer, but who would meet traditional risk factors for skin involvement?
@Sushil Beriwal, is there any thought that if a pa...
As long as dosimetric and clinical criteria are me...